Literature DB >> 7354109

Immunoreactive beta-endorphin in human cerebrospinal fluid.

K Nakao, Y Nakai, S Oki, S Matsubara, T Konishi, H Nishitani, H Imura.   

Abstract

To elucidate the nature of beta-endorphin-like immunoreactivity in human cerebrospinal fluid (CSF) and its relationship with plasma beta-endorphin, plasma and CSF specimens were obtained simultaneously. Gel chromatography revealed that beta-endorphin-like immunoreactivity in CSF consisted of two components with elution positions compatible to those of beta-endorphin and beta-lipotropin (beta-LPH), respectively, and an additional larger molecule. The beta-endorphin level in CSF obtained from four nonendocrine patients was 17.9 +/- 2.3 pg/ml (mean +/- SE) and corresponded to 20% of beta-endorphin-like immunoreactivity. The predominant componet in CSF was either beta-LPH or the larger molecule. beta-Endorphin levels in CSF were consistently higher than those in plasma, and there seemed to be no relationship between them. One patient with Nelson's syndrome had a CSF beta-endorphin level of 14.8 pg/ml, although the plasma level was 784 pg/ml. On the other hand, one patient under glucocorticoid treatment had a CSF beta-endorphin level of 13.0 pg/ml and an undetectably low plasma level. It is concluded that 1) beta-endorphin-like immunoreactivity consists of beta-endorphin, beta-LPH, and possibly the precursor molecule; and 2) there exists marked dissociation between plasma and CSF beta-endorphin levels, suggesting the possible central nervous system origin of beta-endorphin in CSF.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7354109     DOI: 10.1210/jcem-50-2-230

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  13 in total

1.  Determination of beta-endorphin and substance P in small volumes of human cerebrospinal fluid.

Authors:  K Henning; T M Wallasch; H Przuntek
Journal:  J Neural Transm       Date:  1986       Impact factor: 3.575

2.  Anorexia nervosa and exercise. Implications from recent findings.

Authors:  J A Blumenthal; S Rose; J L Chang
Journal:  Sports Med       Date:  1985 Jul-Aug       Impact factor: 11.136

Review 3.  Enkephalins and Endorphins. Clinical, pharmacological and therapeutic implications.

Authors:  D L Copolov; R D Helme
Journal:  Drugs       Date:  1983-12       Impact factor: 9.546

4.  CSF-endorphines in acute and chronic brain lesions.

Authors:  E Hamel
Journal:  Neurosurg Rev       Date:  1988       Impact factor: 3.042

5.  beta-Endorphin: characteristics of binding sites in rabbit spinal cord.

Authors:  P Ferrara; C H Li
Journal:  Proc Natl Acad Sci U S A       Date:  1980-10       Impact factor: 11.205

6.  Immunoreactive beta-endorphin and adrenocorticotropin in human cerebrospinal fluid.

Authors:  K Nakao; S Oki; I Tanaka; K Horii; Y Nakai; T Furui; M Fukushima; A Kuwayama; N Kageyama; H Imura
Journal:  J Clin Invest       Date:  1980-12       Impact factor: 14.808

7.  Isα-endorphin an uremic toxin?α-Endorphin isolated from filtrate of uremic patients with carbohydrate intolerance.

Authors:  T Abiko; H Sekino
Journal:  Amino Acids       Date:  1993-02       Impact factor: 3.520

8.  Stress hormones in accident patients studied before admission to hospital.

Authors:  W Hetz; H D Kamp; U Zimmermann; A von Bohlen; L Wildt; J Schuettler
Journal:  J Accid Emerg Med       Date:  1996-07

9.  Endorphins and exercise.

Authors:  V J Harber; J R Sutton
Journal:  Sports Med       Date:  1984 Mar-Apr       Impact factor: 11.136

10.  Stress hormonal response to exercise after sleep loss.

Authors:  B J Martin; P R Bender; H Chen
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1986
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.